Last reviewed · How we verify
Fentanyl; Buprenorphine; Naloxone
At a glance
| Generic name | Fentanyl; Buprenorphine; Naloxone |
|---|---|
| Sponsor | Janssen-Cilag A.G., Switzerland |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation (PHASE4)
- Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine (PHASE4)
- Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial (PHASE4)
- Suvorexant for Opioid/Stimulant Co-use (PHASE2)
- Low-dose Versus a High-dose Sublingual Buprenorphine Induction (PHASE4)
- Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl (PHASE3)
- Buprenorphine Induction for Fentanyl Dependent Opioid Users (EARLY_PHASE1)
- Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fentanyl; Buprenorphine; Naloxone CI brief — competitive landscape report
- Fentanyl; Buprenorphine; Naloxone updates RSS · CI watch RSS
- Janssen-Cilag A.G., Switzerland portfolio CI